CA3238574A1 - Methods of using interleukin-2 agents - Google Patents
Methods of using interleukin-2 agents Download PDFInfo
- Publication number
- CA3238574A1 CA3238574A1 CA3238574A CA3238574A CA3238574A1 CA 3238574 A1 CA3238574 A1 CA 3238574A1 CA 3238574 A CA3238574 A CA 3238574A CA 3238574 A CA3238574 A CA 3238574A CA 3238574 A1 CA3238574 A1 CA 3238574A1
- Authority
- CA
- Canada
- Prior art keywords
- fold
- seq
- amino acid
- fusion protein
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284978P | 2021-12-01 | 2021-12-01 | |
| US63/284,978 | 2021-12-01 | ||
| US202263348201P | 2022-06-02 | 2022-06-02 | |
| US63/348,201 | 2022-06-02 | ||
| PCT/US2022/080728 WO2023102463A1 (en) | 2021-12-01 | 2022-12-01 | Methods of using interleukin-2 agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3238574A1 true CA3238574A1 (en) | 2023-06-08 |
Family
ID=84981477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3238574A Pending CA3238574A1 (en) | 2021-12-01 | 2022-12-01 | Methods of using interleukin-2 agents |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240041981A1 (https=) |
| EP (1) | EP4440598A1 (https=) |
| JP (1) | JP2024543209A (https=) |
| KR (1) | KR20250169356A (https=) |
| CN (1) | CN120131911A (https=) |
| AU (1) | AU2022399832A1 (https=) |
| CA (1) | CA3238574A1 (https=) |
| MX (1) | MX2024006746A (https=) |
| TW (1) | TW202333772A (https=) |
| WO (1) | WO2023102463A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3147757A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2025221954A1 (en) * | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| CN119638850A (zh) * | 2024-11-07 | 2025-03-18 | 浙江大学 | 双特异性细胞因子融合蛋白及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| PH12017501856B1 (en) * | 2015-04-10 | 2022-08-10 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| KR102687530B1 (ko) | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| SG11201900616UA (en) | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
| US20210017247A1 (en) * | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| CA3147757A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
-
2022
- 2022-12-01 WO PCT/US2022/080728 patent/WO2023102463A1/en not_active Ceased
- 2022-12-01 CN CN202510086918.0A patent/CN120131911A/zh active Pending
- 2022-12-01 EP EP22843966.7A patent/EP4440598A1/en active Pending
- 2022-12-01 JP JP2024532776A patent/JP2024543209A/ja active Pending
- 2022-12-01 US US18/060,725 patent/US20240041981A1/en active Pending
- 2022-12-01 CA CA3238574A patent/CA3238574A1/en active Pending
- 2022-12-01 KR KR1020247021478A patent/KR20250169356A/ko active Pending
- 2022-12-01 AU AU2022399832A patent/AU2022399832A1/en active Pending
- 2022-12-01 MX MX2024006746A patent/MX2024006746A/es unknown
- 2022-12-01 TW TW111146169A patent/TW202333772A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250169356A (ko) | 2025-12-03 |
| JP2024543209A (ja) | 2024-11-19 |
| CN120131911A (zh) | 2025-06-13 |
| WO2023102463A1 (en) | 2023-06-08 |
| TW202333772A (zh) | 2023-09-01 |
| US20240041981A1 (en) | 2024-02-08 |
| EP4440598A1 (en) | 2024-10-09 |
| AU2022399832A1 (en) | 2024-06-06 |
| MX2024006746A (es) | 2024-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112566935B (zh) | 抗ox40抗体和使用方法 | |
| JP7762498B2 (ja) | 修飾重鎖定常領域を含む抗体 | |
| EP3504242B1 (en) | Anti-ox40 antibodies and their uses | |
| JP7089470B2 (ja) | 抗体およびその使用方法 | |
| US20240041981A1 (en) | Methods of using interleukin-2 agents | |
| US20250002601A1 (en) | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 | |
| KR20220051177A (ko) | 인터류킨-2 작용제 및 이의 용도 | |
| CN107250157A (zh) | 包含修饰的重链恒定区的抗体 | |
| US12030951B2 (en) | Anti-OX40 antibody and uses thereof | |
| CN116075525A (zh) | 抗mertk抗体及其使用方法 | |
| JP2022513653A (ja) | 修飾された重鎖定常領域を含む抗体 | |
| CA3193273A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| KR20230129018A (ko) | 인터류킨-2 작용제를 사용하는 방법 | |
| TW202325735A (zh) | 特異性結合cd47及cd20之雙特異性抗體及其用途 | |
| KR20230104611A (ko) | 항-cd94 항체 및 이의 사용 방법 | |
| US20220242962A1 (en) | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 | |
| HK40128460A (zh) | 使用白细胞介素-2药剂的方法 | |
| HK40111234A (zh) | 使用白细胞介素-2药剂的方法 | |
| CN118871123A (zh) | 使用白细胞介素-2药剂的方法 | |
| HK40085344B (zh) | 抗ox40抗体及其用途 | |
| HK40085373A (en) | Anti-cd47 antibody and uses thereof | |
| AU2013203712A1 (en) | Binding Proteins, Including Antibodies, Antibody Derivatives And Antibody Fragments, That Specifically Bind CD154 And Uses Thereof | |
| EA045547B1 (ru) | Антитела к ox40 и способы применения | |
| HK40003363B (en) | Anti-ox40 antibodies and their uses | |
| HK40003363A (en) | Anti-ox40 antibodies and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241107 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251104 |